Table 2 Effect of the experimental treatments on in vitro embryonic development

c-TYH + 0mM MBCD

125

0^a

ND

ND

ND

ND

c-TYH + 0.75mM MBCD

117

91.50 ± 0.72^b

94.67 ± 1.97^a

93.81 ± 0.8^a

91.78 ± 2.71^a

ND

c-TYH + 1mM MBCD

127

93.02 ± 1.72^b

94.86 ± 6.63^a

88.75 ± 4.36^a

86.68 ± 3.40^a

ND

c-TYH + 2mM MBCD

121

95.21 ± 4^b

98 ± 4^a

95.68 ± 1.76^a

92.64 ± 3.35^a

ND

c-TYH + .75mM MBCD + 20ng/ µl pCAG-GFP

134

81.91 ± 7.78^b

99.11 ± 1.79^a

97.54 ± 3.04^a

88.46 ± 4^a

74.72 ± 6.98^a

c-TYH + 1mM MBCD + 20ng/ µl pCAG-GFP

154

83.55 ± 11.81^b

97.34 ± 3.51^a

97.34 ± 1.31^a

91.54 ± 1.75^a

78.92 ± 6.10^a

c-TYH + 2mM MBCD + 20ng/ µl pCAG-GFP

153

91.72 ± 1.5^b

96.36 ± 2.62^a

96.36 ± 2.62^a

94.64 ± 2.11^a

85.46 ± 3.54^a

c-TYH + .75mM MBCD + 20ng/ µl pgRNA-Cas9

173

94.12 ± 1.57^b

95.33 ± 7.80^a

95.33 ± 3.19^a

95.33 ± 3.19^a

82.68 ± 10.19^a

c-TYH + 1mM MBCD + 20ng/ µl pgRNA-Cas9

195

92.03 ± 3.39^b

95.28 ± 6.53^a

93.15 ± 3.7^a

90.70 ± 4.67^a

86.86 ± 6.79^a

c-TYH + 2mM MBCD + 20ng/ µl pgRNA-Cas9

231

92.69 ± 1.19^b

97.92 ± 3.79^a

95.65 ± 1.61^a

90.79 ± 4.13^a

91.64 ± 3.6^a

HTF + 0.4%BSA + 3%DMSO + 20ng/ µl pCAG-GFP

121

86.75 ± 6.17^b

97.73 ± 4.55^a

97.5 ± 2.5^a

97.5 ± 2.5^a

48.11 ± 4.66^b

HTF + 0.4% BSA + 3% DMSO + 20ng/ µl pgRNA-Cas9

179

86.55 ± 3.24^b

97.37 ± 6.45^a

94.63 ± 3.63^a

90.70 ± 4.38^a

42.56 ± 1.74^b

HTF + 0.4%BSA

140

89.07 ± 3.54^b

98.90 ± 1.51^a

97.44 ± 1.17^a

97.5 ± 1.17^a

ND